Majory

Majory is a biotechnology company based in Paris, France, dedicated to developing first-in-class small molecule therapeutics for autoimmune and inflammatory diseases. The company focuses on the modulation of the Major Histocompatibility Complex (MHC) class II pathway, which is central to the initiation of adaptive immune responses. By targeting specific HLA-DR variants, Majory aims to prevent the presentation of self-antigens to T-cells, thereby restoring immune tolerance. This precision medicine approach is designed to provide a more targeted alternative to broad-spectrum immunosuppressants, potentially offering improved safety and efficacy. Founded by industry veteran Jean-Jacques Garaud, the company leverages deep expertise in immunology and drug development. Majory is currently advancing its lead programs through the pre-clinical stage.